New Gene Therapy for Huntington's Disease
Latus Bio’s preclinical study demonstrates that targeting the MSH3 protein may slow the progression of Huntington’s disease.
Updated on Oct. 28, 2026 in Biotech
Live Poll
Does genetic-based research offer the best hope for treating complex, hereditary neurodegenerative diseases?
Latus Bio published research in Nature Communications detailing a gene therapy candidate for Huntington's disease. The preclinical study describes how the candidate, LTS-201, reduces MSH3 expression in neurons to address somatic instability.
Why it matters
By targeting MSH3, a protein driver of disease progression, this approach seeks to halt or slow the clinical decline of Huntington's disease. The methodology provides a potential framework for treating other repeat expansion disorders.
LTS-201 demonstrated a 48% to 94% reduction of MSH3 mRNA in non-human primates, with over 90% of medium spiny neurons showing MSH3 knockdown. Researchers project a 50% to 120% reduction in the rate of cUHDRS clinical decline.
The players
Latus Bio
A Philadelphia and Boston-based biotechnology company focused on developing AAV gene therapies to target somatic instability in neurodegenerative diseases.
The details
LTS-201 is an adeno-associated virus gene therapy candidate that uses an engineered capsid to target medium spiny neurons and cortical projection neurons. It functions by delivering an artificial microRNA designed to silence the MSH3 gene, which is a known driver of somatic instability in patients with mutant HTT. The therapeutic model was validated using human natural history data and computational simulations of neuronal expansion.
Timeline
October 28, 2026: Latus Bio announced the publication of its peer-reviewed study.
2025: Prior research detailed the development of the AAV-DB-3 engineered capsid.
The Tech Race
This development shifts the focus of Huntington's research from silencing the HTT protein itself to managing the somatic instability caused by MSH3. It establishes a new computational framework that could potentially be applied to other repeat expansion disorders like myotonic dystrophy type 1.
This is a preclinical research development and is not currently available for patient use. The potential clinical benefit is aimed at more than 100,000 Huntington's patients, with researchers suggesting that earlier intervention will likely produce the greatest therapeutic results.
The takeaway
Targeting MSH3 represents a specific strategy to address the root of Huntington's disease progression rather than its symptoms. Interested observers should monitor for follow-up human clinical trial filings from Latus Bio.
Further reading
For broader trends in genetic medicine, visit our Biotech section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Does genetic-based research offer the best hope for treating complex, hereditary neurodegenerative diseases?
